UNSPSC 51294203: Fenmetramide

This classification denotes an antidepressant agent with the molecular formula C11H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WCH9HW127L, chemically known as 3-morpholinone, 5-methyl-6-phenyl- but generally known as fenmetramide, which bears US NIH Compound Identifier 21789. European Medicines Agency schedules Fenmetramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07572MIG. The term FENMETRAMIDE is an International Non-Proprietary Name.

UNSPSC 51294203 Fenmetramide is a Commodity code that nominally covers a specific pharmaceutical active ingredient, but recent state and local solicitations show little activity aligned with fenmetramide procurement itself. The code appears underutilized or misclassified in the state and local system; the three recent opportunities posted under this code actually solicit naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products—none of which target fenmetramide specifically. Issuing bodies include a Florida county health authority (Seminole County), a state health agency (Texas Health and Human Services Commission), and a multistate cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance / MMCAP). The mismatch between the code's nominal scope and actual procurement activity signals either a classification error in the state and local procurement system or that fenmetramide is acquired so infrequently under this code that it does not drive recent solicitation volume.

Recent opportunities span Florida, Texas, and Minnesota through different procurement mechanisms. Seminole County issued an IFB (IFB60459723LAS) on June 30, 2026, with a response deadline of July 26, 2023, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building in Sanford, Florida, with a two-year initial term and optional one-year renewal. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, designed as foundational market intelligence before formal RFP issuance. MMCAP, administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, including Oregon, with contract effectiveness set for July 1, 2026. The code shows no identifiable recent activity for fenmetramide itself.